An interventional study of Progestin-Primed Ovarian Stimulation (PPOS) and GnRH Antagonist Protocol in Polycystic Ovary Syndrome (PCOS) and Female Infertility, sponsored by Hanoi General Hospital (Vietnam). Recruiting at 1 site in Vietnam. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Hanoi General Hospital (Vietnam) · Not applicable, Interventional, and Treatment
This study aims to compare the outcomes of two ovarian stimulation protocols used in in vitro fertilization (IVF): the progestin-primed ovarian stimulation (PPOS) protocol and the GnRH antagonist protocol.
944 studies on the registry are indexed under Polycystic Ovary Syndrome; 174 are open to participants now.
This study's planned enrollment of 400 is above the median of 70 across 685 interventional studies indexed under Polycystic Ovary Syndrome.
Browse Polycystic Ovary Syndrome studies →This is the only study on the registry with Hanoi General Hospital (Vietnam) as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants receive ovarian stimulation using the progestin-primed ovarian stimulation (PPOS) protocol for in vitro fertilization.
Drug: Progestin-Primed Ovarian Stimulation (PPOS)
Participants receive ovarian stimulation using a GnRH antagonist protocol for in vitro fertilization.
Drug: GnRH Antagonist Protocol
Ovarian stimulation using a progestin-primed ovarian stimulation (PPOS) protocol, including gonadotropins combined with oral progestin for pituitary suppression during in vitro fertilization treatment.
Ovarian stimulation using a gonadotropin-releasing hormone (GnRH) antagonist protocol for pituitary suppression during in vitro fertilization treatment.
Ongoing pregnancy rate at 12 weeks
Ongoing pregnancy defined as a viable intrauterine pregnancy with fetal cardiac activity confirmed by ultrasound at or beyond 12 weeks of gestation.
Time frame: Up to 12 weeks after embryo transfer
Number of Oocytes Retrieved
Total number of oocytes retrieved per ovarian stimulation cycle at the time of oocyte retrieval
Time frame: From ovarian stimulation start to oocyte retrieval (approximately 10-14 days)
Number of Mature (MII) Oocytes
Number of mature oocytes at the metaphase II (MII) stage identified at the time of oocyte retrieval
Time frame: At the time of oocyte retrieval (approximately 10-14 days after stimulation start)
Live birth rate
Live birth rate of live-born infants at ≥24 weeks of gestation or with birth weight ≥500 g and signs of life after birth.
Time frame: Up to delivery (approximately 9-12 months after embryo transfer)
Clinical pregnancy rate
Clinical pregnancy defined as the presence of a gestational sac with fetal cardiac activity confirmed by ultrasound
Time frame: 6-7 weeks after embryo transfer
Fertilization Rate
Fertilization rate, defined as the percentage of fertilized oocytes
Time frame: 16-18 hours after oocyte insemination
Number of Usable Embryos
Time frame: From fertilization to embryo assessment (approximately Day 3 to Day 5 after oocyte retrieval).
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.